Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: J Steroid Biochem Mol Biol. 2019 Jun 19;193:105415. doi: 10.1016/j.jsbmb.2019.105415

Fig. 11.

Fig. 11.

Combined therapy with JD128 and anti-PD-L1 antibody enhance tumor infiltrating dendritic cells and M1 macrophages. Single cell suspensions were purified, stained and analyzed by cyTOF as described above. Groups include mice treated with control vehicle (CON), anti-PD-L1 antibody (Ab), fulvestrant (Fulv), JD128 or the combination of fulvestrant with anti-PD-L1 antibody (Fulv+Ab) or JD128 and anti-PD-L1 antibody (JD128 + Ab). A) Subset of dendritic cells present in the tumor bed show a significant increase in the total number of DC gated as (CD45+CD11c+MHCII+) when SERD JD128 was added to ICI therapy. B) M1 tumor infiltrating macrophages were significantly increased by combination therapy of SERD JD128 and anti-PD-L1 antibody. Macrophages were gated as (CD45+CD11b+F4/80+ M1: MHCIIhi M2: MHCIIlo). *P ≤ 0.05, **** P < 0.0001, n= 6–11.